CJC-1295 + Ipamorelin Blend
The clinic-standard GH-axis pairing that combines a GHRH analog and a selective GHRP in one vial to amplify the body's own growth hormone pulses through two separate receptors.
CJC-1295 + Ipamorelin is a pre-mixed two-peptide combination: CJC-1295 (a modified GRF 1-29 GHRH analog) supplies the GHRH-receptor signal while Ipamorelin (a selective ghrelin/GHS receptor agonist) supplies the GHRP-receptor signal. Hitting both arms of growth hormone release at once produces a substantially larger, but still pulsatile, GH pulse than either peptide alone. It is the most common GH-axis stack in peptide-clinic practice, valued for a cleaner side-effect profile than exogenous HGH, though direct fixed-blend outcome trials remain absent.
Class
GHRH analog + GHRP (ghrelin receptor agonist) blend
Half-life
CJC-1295 ~30 min; Ipamorelin ~2 hours (combined effective window 2-3 hours)
Routes
Subcutaneous, Intramuscular
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Synergistic GH pulse amplification
Because CJC-1295 activates the GHRH receptor and ipamorelin activates the ghrelin/GHS receptor on the same pituitary somatotrophs, combined activation produces a roughly 3-5x larger GH pulse than either peptide alone. This dual-receptor synergy is established pharmacology, not controversial.
Improved sleep depth
The most consistent subjective win reported across clinic and community use is deeper sleep, consistent with GH release being tied to slow-wave sleep. Bedtime dosing is the most common schedule specifically to align with the natural nocturnal GH pulse.
Training recovery
Users and clinics report improved recovery from training over weeks to months. The effect is pharmacologically plausible through GH-axis signaling, though it rests more on distributed practice experience than controlled blend trials.
Modest body-composition shifts
Body-composition changes over 3-6 months are described as real but modest rather than dramatic, reflecting endogenous pulsatile GH stimulation rather than supraphysiologic exogenous hormone.
Cleaner hormonal profile than older GHRPs
Ipamorelin's selectivity means it does not meaningfully spike cortisol or prolactin, which is precisely why it is paired with CJC-1295 rather than GHRP-2 or GHRP-6. This selectivity was established by Raun in 1998.
Gentler than exogenous HGH by mechanism
Rather than delivering a flat, sustained supraphysiologic dose of growth hormone, the blend amplifies the body's own pulsatile release, so peak GH is lower and the side-effect profile is mechanistically gentler, along with lower cost and lower regulatory exposure.
Mechanism
How it works
The blend targets both arms of growth hormone release simultaneously. CJC-1295, a modified GRF 1-29 GHRH analog, binds the GHRH receptor on pituitary somatotrophs to trigger GH release. Ipamorelin, a selective pentapeptide GHRP, binds the ghrelin/growth hormone secretagogue (GHS) receptor, a separate receptor family, to amplify the same pulse. Because the two signals converge on GH-producing cells through independent pathways, their combined effect is synergistic rather than merely additive.
The result is amplification of GH pulse amplitude, on the order of 3-5x compared with either component alone. Importantly, the combination is best described as increasing the size of the pulse, not the frequency of pulses, and the release remains pulsatile and endogenous. This preserves the body's own pulse pattern, in contrast to exogenous HGH which delivers a flat dose that over time can flatten the pituitary's natural rhythm.
Ipamorelin's defining feature is selectivity. Unlike earlier GHRPs such as GHRP-2 and GHRP-6, it stimulates GH without meaningfully raising cortisol or prolactin, giving the blend a cleaner endocrine profile. The two peptides also differ pharmacokinetically: CJC-1295 (no DAC) clears in about 30 minutes while ipamorelin persists roughly 2 hours, producing a combined effective window of about 2-3 hours per injection.
A practical caveat concerns the fixed blend itself. CJC-1295 (3367.9 Da) and ipamorelin (711.85 Da) are very different molecules and can degrade at different rates once reconstituted, so the labeled peptide ratio may not hold indefinitely in solution. Ratio durability depends on formulation, storage, and time after reconstitution and is source-specific rather than independently established.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Reconstitute per vendor instructions with bacteriostatic water. Store refrigerated after reconstitution. Because the two peptides can degrade at different rates in solution, use within the vendor-specified window.
Beginner
- Dose
- Per-vendor pre-dosed amount (equivalent to roughly 100 mcg CJC-1295 + 100-200 mcg ipamorelin per injection)
- Frequency
- Once daily
- Timing
- At bedtime, on an empty stomach (fast 2+ hours before injection)
- Duration
- 8-12 weeks
- Route
- Subcutaneous
Single bedtime injection following vendor dosing instructions; aligns with the natural nocturnal GH pulse.
Intermediate
- Dose
- Per-vendor pre-dosed amount per injection
- Frequency
- Twice daily
- Timing
- Morning (fasted) and bedtime
- Duration
- 12 weeks
- Route
- Subcutaneous
Two injections daily per vendor instructions; inject on an empty stomach.
Advanced
- Dose
- Per-vendor pre-dosed amount per injection
- Frequency
- Twice daily
- Timing
- Morning (fasted) and bedtime
- Duration
- 16 weeks
- Route
- Subcutaneous
Can add MK-677 25 mg oral at bedtime for sustained 24-hour GH elevation.
- There is no FDA-approved dosing framework for either component or the blend; community route and schedule figures are practice patterns, not label instructions.
- Inject on an empty stomach, since food (and especially fats and carbohydrates) can blunt the GH pulse.
- Typical cycle length is 8-16 weeks; the blend can be used long-term with periodic ~4-week breaks.
- Pre-blended ratios are typically fixed, so standard dosing is used regardless of body weight.
- The pre-mixed vial simplifies dosing compared with reconstituting and drawing two separate peptides.
Evidence
Research & clinical studies (1)
Ipamorelin, the first selective growth hormone secretagogue
Established ipamorelin as a selective GH secretagogue that releases growth hormone without significantly elevating cortisol or prolactin, the basis for pairing it with CJC-1295.
Combinations
Stacking & blends
CJC-1295 + Ipamorelin (the core blend)
Synergistic pulsatile GH release
GHRH-plus-GHRP stacking activates two separate receptor pathways on pituitary somatotrophs, producing a 3-5x larger GH pulse than either arm alone while ipamorelin's selectivity keeps cortisol and prolactin low.
Blend + MK-677
Sustained 24-hour GH elevation
Adding oral MK-677 (ibutamoren) 25 mg at bedtime extends GH secretagogue activity across the full day, used in advanced protocols; listed as compatible in interaction data.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer
- Pituitary disorders
- Pregnancy or breastfeeding
The side-effect profile is generally mild and consistent with the individual components. Compared with older GHRPs, the cortisol and prolactin profile is cleaner. Sermorelin is flagged as a caution when combined. Source quality is part of the risk picture: research-vendor products are not FDA-reviewed, and mislabeled peptide products have been documented in market analyses, so certificate-of-analysis verification matters.
FAQ
CJC-1295 + Ipamorelin Blend — common questions
What is the CJC-1295 / Ipamorelin blend?
A combination of two growth hormone-stimulating peptides in a single vial: CJC-1295 (a modified GHRH analog) and ipamorelin (a selective ghrelin/GHS receptor agonist). Together they hit both arms of GH release, the GHRH side and the GHRP side, for synergistic pulsatile GH stimulation.
What does the blend do?
It stimulates pulsatile growth hormone release through two complementary pathways. CJC-1295 triggers GH release from pituitary somatotrophs via the GHRH receptor, and ipamorelin amplifies the pulse via the ghrelin receptor. Sleep, recovery, skin, and body-composition claims are mostly clinic and community reports layered on component pharmacology rather than direct blend RCT outcomes.
How is it typically administered?
By subcutaneous or intramuscular injection, most commonly once or twice daily with a bedtime injection being the most common, on an empty stomach. Research and clinic formulations vary and there is no FDA-approved dosing framework, so route and schedule figures should be treated as practice patterns, not label instructions.
How does the blend compare to straight HGH?
It is a different model. Straight HGH delivers exogenous growth hormone at a flat dose that can flatten the pituitary's own pulse pattern over time, whereas the blend amplifies the body's own pulse through two receptors. Peak GH is lower than with HGH, but the side-effect profile is mechanistically gentler and cost and regulatory exposure are lower.
What are the side effects?
Generally mild and consistent with the individual components: transient flushing at the injection site, mild water retention, occasional ghrelin-driven hunger from the ipamorelin half, mild headache, and occasional injection-site soreness. The cortisol and prolactin profile is cleaner than older GHRPs.
Is the blend FDA approved?
No. Neither component is FDA-approved for any indication and the blend has no approved use. In October 2024 the FDA PCAC voted against ipamorelin for 503A compounding inclusion. Both are sold as research chemicals and are prohibited under WADA for competitive athletes.
Does it actually work?
Yes on receptor logic, less settled on clinical endpoints. GHRH-plus-GHRP synergy is established pharmacology and ipamorelin's clean profile was documented by Raun in 1998, but a formal fixed-blend RCT with outcome endpoints has not been done, so the most rigorous evidence is at the component level.
